title: Preliminary results of concurrent methotrexate, cisplatin and radiation treatment for locally advanced urothelial cancers.
abstract: Ten patients with invasive bladder cancer and one with locally advanced renal pelvic cancer were treated with concurrent methotrexate, cisplatin and radiotherapy. Methotrexate 30 mg/m2 was administered intravenously on the day of the initiation of radiotherapy and cisplatin 70 mg/m2 on the second day. The number of chemotherapy cycles delivered was 1 in 7 patients and 2 in 4. The median dose of radiation was 50 Gy. Of 11 patients, 7 (64%) achieved a partial response and 4 had no change in disease. The median duration of response was 16 months for patients with a partial response. Six patients with a partial response (55%) are alive for a median of 22.5 months and 2 of 4 with no change are alive for 4 and 15 months, respectively. Leukopenia less than 3000 cell/mm3 was observed in 4 (36%) and thrombocytopenia less than 100,000 cells/mm3 in 3 (27%). Local control could be achieved safely with concurrent methotrexate, cisplatin and radiation therapy in patients with locally advanced urothelial cancer who were unsuitable for surgery.
authors.affiliation: Department of Urology, Shimane Medical University, Izumo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Igawa
authors.forename: S
authors.initials: S
authors.lastname: Urakami
authors.forename: H
authors.initials: H
authors.lastname: Shirakawa
authors.forename: H
authors.initials: H
authors.lastname: Shiina
authors.forename: H
authors.initials: H
authors.lastname: Kishi
authors.forename: Y
authors.initials: Y
authors.lastname: Himeno
authors.forename: T
authors.initials: T
authors.lastname: Ishibe
authors.forename: H
authors.initials: H
authors.lastname: Kadena
authors.forename: T
authors.initials: T
authors.lastname: Usui
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007680:Kidney Neoplasms / Q000628:therapy*; D007682:Kidney Pelvis; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011879:Radiotherapy Dosage; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D002945:Cisplatin; D008727:Methotrexate